Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H17N |
| Molecular Weight | 175.2701 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1(CCCCC1)C2=CC=CC=C2
InChI
InChIKey=RGZGRPPQZUQUCR-UHFFFAOYSA-N
InChI=1S/C12H17N/c13-12(9-5-2-6-10-12)11-7-3-1-4-8-11/h1,3-4,7-8H,2,5-6,9-10,13H2
| Molecular Formula | C12H17N |
| Molecular Weight | 175.2701 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals. | 2003 Mar |
|
| [Effects of blockade of ionotropic glutamate receptors on the development of pentylenetetrazole kindling in mice]. | 2005 Nov |
|
| Effects of ionotropic glutamate receptor channel blockers on the development of pentylenetetrazol kindling in mice. | 2007 Jan |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:30:38 GMT 2023
by
admin
on
Sat Dec 16 09:30:38 GMT 2023
|
| Record UNII |
HBO2D49I2S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DEA NO. |
7460
Created by
admin on Sat Dec 16 09:30:38 GMT 2023 , Edited by admin on Sat Dec 16 09:30:38 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30176449
Created by
admin on Sat Dec 16 09:30:38 GMT 2023 , Edited by admin on Sat Dec 16 09:30:38 GMT 2023
|
PRIMARY | |||
|
31862
Created by
admin on Sat Dec 16 09:30:38 GMT 2023 , Edited by admin on Sat Dec 16 09:30:38 GMT 2023
|
PRIMARY | |||
|
2201-24-3
Created by
admin on Sat Dec 16 09:30:38 GMT 2023 , Edited by admin on Sat Dec 16 09:30:38 GMT 2023
|
PRIMARY | |||
|
HBO2D49I2S
Created by
admin on Sat Dec 16 09:30:38 GMT 2023 , Edited by admin on Sat Dec 16 09:30:38 GMT 2023
|
PRIMARY | |||
|
DB01506
Created by
admin on Sat Dec 16 09:30:38 GMT 2023 , Edited by admin on Sat Dec 16 09:30:38 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
This metabolite was detected in rat urine. However, according to this journal acticle, “The authors' experience in metabolism and analytical studies on rats and humans support the assumption that the metabolites found in rat urine should also be present in human urine. Therefore, it can be concluded that the procedure described here should also be applicable for human urine screening for PCEEA and/or PCMEA in clinical or forensic cases. However, their differentiation would only be possible through detection of the respective parent drug or unique metabolites.”
URINE
|
||
|
PARENT -> METABOLITE |
This metabolite was detected in rat urine. However, according to this journal acticle, “The authors' experience in metabolism and analytical studies on rats and humans support the assumption that the metabolites found in rat urine should also be present in human urine. Therefore, it can be concluded that the procedure described here should also be applicable for human urine screening for PCEEA and/or PCMEA in clinical or forensic cases. However, their differentiation would only be possible through detection of the respective parent drug or unique metabolites.”
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
